- blurred vision
Other side effects that may occur with topical corticosteroids include dry skin, skin irritation, dermatitis, dermatitis around the mouth, and mild dilation of small blood vessels (capillaries).
Withdrawal Reaction from Steroids:
If you use this medication continuously for prolonged periods, a withdrawal reaction may occur when treatment is stopped, with some of the following symptoms: skin redness that may extend beyond the initially treated area, burning or itching sensation, intense itching, skin peeling, open sores that suppurate.
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish System of Pharmacovigilance of Medicines for Human Use, https://www.notificaRAM.es.By reporting adverse effects, you can contribute to providing more information on the safety of this medication
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after “CAD”.The expiration date is the last day of the month indicated.
No special storage conditions are required. Do not refrigerate or freeze.
Once opened, discard the tube with the remaining cream after 12 weeks.
Medications should not be disposed of through drains or trash. Deposit the packaging and medications you no longer need at the SIGRE collection pointat the pharmacy.If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition ofMometasona Viso Pharmaceutical
Appearance of the product and contents of the package
Mometasona Viso Pharmaceutical is a white, soft, and translucent cream.
It is available in tubes containing 10 g, 15 g, 20 g, 30 g, 50 g, 60 g, or 100 g of cream.
Only some package sizes may be commercially marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Glenmark Arzneimittel GmbH
Industriestr. 31,
82194 Gröbenzell,
Germany
Responsible for manufacturing
Salutas Pharma GmbH
Otto-von Guericke-Allee 1
D-39179 Barleben, Germany
or
Glenmark Pharmaceuticals Europe Limited,
Building 2, Croxley Green Business Park, Croxley Green,
Hertfordshire, WD18 8YA, United Kingdom
or
Glenmark Pharmaceuticals S.R.O.
Fibichova, 143 56617
Vysoke Myoto,
Czech Republic
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Viso Pharmaceutical, S.L.U.
C/ Retama 7, 7th Floor,
28045 Madrid,
Spain
This medication is authorized in the EEA member states with the following names:
Denmark Mometasonfuroat Glenmark 1 mg/g Creme
Finlandia Mometasonifuroaatti Glenmark 1mg/g emulsiovoide
Germany Mometasonfuroat Glenmark 1 mg/g Creme
Italy Mometasone Glenmark 1 mg/g Crema
Norway Mometason Glenmark 0.1%Krem
Spain Mometasona Viso Pharmaceutical1mg/g cream
Sweden Mometason Glenmark 1mg/g kräm
United Kingdom Mometasone Furoate 0.1% w/w Cream
PolandEztom, 1 mg/g, Cream
Last review date of this leaflet: February 2023
Detailed and updated information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.